期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲磺酸伊马替尼治疗难治性或复发性Ph阳性急性白血病2例报告

下载PDF
导出
作者 杨桂玲 余莉 曹瑞生
机构地区 江西医学院第二附属医院血液科
出处 《实用癌症杂志》 2005年第5期533-534,共2页 The Practical Journal of Cancer
关键词 甲磺酸伊马替尼 费城染色体 白血病 急性
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Voneken JW, Kaartinen V, Pattenngale Pk, et al. ber/abl P210 and P190 cause distinct leukemia in transgenic mice[J]. Blood,1995,86(4) : 4603.
  • 2Hago PM, Talpaz M, Dhingra K, et al. Significance of the P210 versus P190 molecular abnormalities in adults with philadelphia chromosome-positive acute leukemia [ J ]. Blood, 1991, 78 (9) :2411.
  • 3Kantarjian H,sawyers C,Hochhaus A,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia[J]. N Engl J Med,2002,34(6):645.
  • 4Talpaz M, Siliver RT, Druker BJ,et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia:result of a phase 2 study[J].Blood, 2000,99(6) : 1928.
  • 5Sawyers CL, Hoehhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase Ustudy [J]. Blood, 2002,99 ( 11 ) : 3530.
  • 6Druker BJ, Lydon NB. Lessons learned from the development of an Ab1 tyrosine kinase inhibitor for chronic myelogenous leukemial[J].J Clin Invest,2000,105(1) :3.
  • 7Sacchi S, Kantarjian HM, O'brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastie phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients[J]. Cancer, 1999,86(6) :2632.
  • 8Hagop M, Cortes J. Lmatinib mesylate (STI 571) therapy for philadelphia chromosome-positive chronic myelogenous leukemia in blast phase[J]. Blood, 2002,99 (10) : 3547.
  • 9孟凡义,郑维扬,刘晓力,宋兰林,徐兵,张钰,黄芬.格列卫联合HA方案治疗20例Ph染色体阳性急性白血病[J].癌症,2003,22(8):840-843. 被引量：11
  • 10Druker BJ,Sanyers CL, Kanlarjian H, et al. Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with philadephia chromosome[J]. N Engl J Med,2001,34(14) :1038.

二级参考文献16

  • 1Cancer Therapy Evaluation Program. Common toxicity criteria,Version 2.0. Bethesda. Md: National Cancer Institute, March 1998.
  • 2Saeehi S, Kantarjian HM, O'brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients Cancer [J]. 1999, 86:2632 - 2641.
  • 3Griesshammer M, Heine B, Hellmann A, et al. Chronic myelogenous leukemia blast crisis: retrospective analysis of prognostic factors in 90 patients [J] . Ann Hematol, 1996, 73:225 - 230.
  • 4Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy [J]. N Engl J Med,2002,34:683 - 693.
  • 5Kantarjian HM, O'brien S, Cortes J, et al. Treatment of accelerated phase of philadelphia chromosome positive chronic myeloid leukemia (ph^+CM-Ap) with imatinib mesylate(STI 571) [J] .Blood,2001, 98 ( 11 ) : 141a.
  • 6Talpaz M, Richard T. Imatinib induces durable hematologic and Cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study [J]. Blood, 2002, 99(6)1928.
  • 7Rosti G, Alberti D, De Vivo A, et al. Hematologic, cytogenetic and molecular response to Glivec (Formerly STI571 ) in Ph^+ chronic myeloid leukemia (CML) in accelerated and blastic phase(AP, BP): a prospective study of the Italian cooperative study of the Italian cooperative study group on CML [J]. Blood, 2001, 98(11): 138a.
  • 8Brian J, Charles L, Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome[J]. N Engl J Med, 2001,344(14):1038.
  • 9Charles L, Hochhaus A. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study [J].Blood, 2002, 99(10) : 3530 - 3539.
  • 10Hagop M, Cortes J. Imatinib mesylate (STI 571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase [ J ]. Blood, 2002, 99 (1O) : 3547 - 3553.

共引文献10

实用癌症杂志
2005年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部